163 related articles for article (PubMed ID: 35437232)
1. A new era has dawned for persons with cystic fibrosis; however many knowledge gaps exist in our efforts to improve care.
Hadjiliadis D; Clausen ES
J Cyst Fibros; 2022 May; 21(3):383-384. PubMed ID: 35437232
[No Abstract] [Full Text] [Related]
2. ELX/TEZ/IVA use in cystic fibrosis liver disease: Is the perspective of improved lung function worth the risk?
Gardiner A; Volovets A; Haber P; Jo H; Visser S; Yozghatlian V; Taylor N; Nolan S; Dentice R; Malouf M; Marinelli T; Sivam D
J Cyst Fibros; 2022 Sep; 21(5):881-884. PubMed ID: 35760705
[No Abstract] [Full Text] [Related]
3. CFTR Modulator Therapy for Cystic Fibrosis.
Grasemann H
N Engl J Med; 2017 Nov; 377(21):2085-2088. PubMed ID: 29099349
[No Abstract] [Full Text] [Related]
4. Triple CFTR Modulator Therapy for Cystic Fibrosis.
Holguin F
N Engl J Med; 2018 Oct; 379(17):1671-1672. PubMed ID: 30334694
[No Abstract] [Full Text] [Related]
5. Beyond cystic fibrosis transmembrane conductance regulator therapy: a perspective on gene therapy and small molecule treatment for cystic fibrosis.
Schneider-Futschik EK
Gene Ther; 2019 Sep; 26(9):354-362. PubMed ID: 31300729
[TBL] [Abstract][Full Text] [Related]
6. Promising new era dawns for cystic fibrosis treatment.
Corbyn Z
Lancet; 2012 Apr; 379(9825):1475-6. PubMed ID: 22530244
[No Abstract] [Full Text] [Related]
7. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
8. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis.
Burgener EB; Moss RB
Curr Opin Pediatr; 2018 Jun; 30(3):372-377. PubMed ID: 29538046
[TBL] [Abstract][Full Text] [Related]
9. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
10. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
11. Incidence of breast cancer in people with cystic fibrosis: A cause for concern?
FitzMaurice TS; Nazareth DS
J Cyst Fibros; 2022 Sep; 21(5):890. PubMed ID: 34866012
[No Abstract] [Full Text] [Related]
12. Entering the era of highly effective CFTR modulator therapy.
Zemanick ET; Accurso FJ
Lancet; 2019 Nov; 394(10212):1886-1888. PubMed ID: 31679947
[No Abstract] [Full Text] [Related]
13. Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.
Shaw N; Collins S; Smith T; McCulloch A; Ketchell I; Edwards V; Blaikie L; Daniels T
Br J Hosp Med (Lond); 2021 Nov; 82(11):1-6. PubMed ID: 34817261
[TBL] [Abstract][Full Text] [Related]
14. Impact of novel CFTR modulator on sinonasal quality of life in adult patients with cystic fibrosis.
Douglas JE; Civantos AM; Locke TB; Sweis AM; Hadjiliadis D; Hong G; Dorgan DJ; Kohanski MA; Palmer JN; Adappa ND
Int Forum Allergy Rhinol; 2021 Feb; 11(2):201-203. PubMed ID: 33070454
[No Abstract] [Full Text] [Related]
15. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
[TBL] [Abstract][Full Text] [Related]
16. Carrier screening for cystic fibrosis in the new era of medications that restore CFTR function.
Massie J; Castellani C; Grody WW
Lancet; 2014 Mar; 383(9920):923-5. PubMed ID: 23992917
[No Abstract] [Full Text] [Related]
17. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
18. Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Flume PA; Biner RF; Downey DG; Brown C; Jain M; Fischer R; De Boeck K; Sawicki GS; Chang P; Paz-Diaz H; Rubin JL; Yang Y; Hu X; Pasta DJ; Millar SJ; Campbell D; Wang X; Ahluwalia N; Owen CA; Wainwright CE;
Lancet Respir Med; 2021 Jul; 9(7):733-746. PubMed ID: 33581080
[TBL] [Abstract][Full Text] [Related]
19. A multidisciplinary model for prenatal care for patients with cystic fibrosis in the era of highly effective modulator therapy.
Li SS; Buschur E; Thung SF; Patel AV; Kirkby S
J Cyst Fibros; 2023 Sep; 22(5):806-810. PubMed ID: 37019745
[No Abstract] [Full Text] [Related]
20. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
